Vaxon Biotech appoints founder as chief executive
April 8, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Konstantinos Kosmatopoulos, vaxon biotech
Paris-based Vaxon Biotech has announced its founder Dr Konstantinos Kosmatopoulos is moving from his current role as chief scientific officer …
Takeda expands in the United Arab Emirates
April 7, 2015Medical Communications, Sales and Marketing Dubai, NEMEA, Singapore, Takeda, UAE, United Arab Emirates, near east
Takeda has opened new UAE offices in Dubai amidst plans to expand its business in the Middle East. The Japanese …
Antibiotic resistance outbreak ‘could kill 80,000’, report warns
April 7, 2015Research and Development, Sales and Marketing AMR, Nabriva Therapeutics, antibiotic resistance, bacteria, blood infections, infections
An antibiotic-resistant blood infection outbreak could lead to 80,000 deaths, according to a government report on threats to the UK. …
Hundreds of jobs threatened after big pharma deals close
April 7, 2015Medical Communications, Research and Development, Sales and Marketing Deals, GSK, Jobs, Novartis, US, Valeant, job losses, redundancy, salix
Fresh from deals worth a combined $34 billion, GSK and Salix Pharmaceuticals have announced company restructures that have placed more …
Refining UK market access
April 7, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, UK, health, market access
“Some people have said NICE needs to change, it needs to create a new vision, but we say we need …
BMS enters gene therapy development deal
April 7, 2015Research and Development BMS, Bristol-Myers Squibb, R&D, cardiovascular disease, cvd, heart disease, heart failure, uniQure
Bristol-Myers Squibb (BMS) has signed a multi-million dollar agreement with Amsterdam-based gene therapy firm uniQure to boost research into new …
Shire plots new ADHD drug approval
April 7, 2015Sales and Marketing ADHD, FDA, SHP465, Shire, Vyvanse, clinical trials, paediatrics
Shire is launching a new clinical trial as part of its FDA submission for a potential ADHD treatment. The company …
Merck Ebola vaccine safe and effective in latest trials
April 2, 2015Research and Development, Sales and Marketing Ebola, Merck, National Institutes of Health, VSV-ZEBOV, Vaccine, Walter Reed Army Institute of Research, newlink
Merck and NewLink’s experimental Ebola vaccine has been found to be safe and effective in a new trial in the …
Merck Serono signs antimalarial development deal
April 2, 2015Research and Development, Sales and Marketing DDD107498, Medicines for Malaria Venture, Merck Serono, antimalarial, malaria
Merck Serono and Medicines for Malaria Venture (MMV) have signed an agreement which will see them advance the development of …
Multiple sclerosis studies underway using existing drugs
April 2, 2015Research and Development, Sales and Marketing MS, Midamor, Prozac, Rilutek, Sanofi, amiloride, covis, fluoxetine, multiple sclerosis, riluzole
Three existing drugs that fight heart disease, depression and motor neurone disease could be used to treat multiple sclerosis (MS) …
Working Life: GlaxoSmithKline’s Thomas Webb
April 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Hong Kong, Working Life, macau, oncology, thomas webb
Thomas Webb, launch lead for GSK oncology Hong Kong and Macau How did you find your way into your current role? …
Novartis accused of Lucentis ‘campaign’ against Avastin
April 2, 2015Sales and Marketing Lucentis, NHS, Novartis, avastin, bevacizumab, ranibizumab, wet AMD
Novartis “embarked on a campaign to undermine and divert attention” from a cheap drug for vision loss and maintain the …
PM Society appoints two new members
April 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing colin williams, jonathan dancer, pm society
Not-for-profit healthcare marketing organisation PM Society has made two new appointments to its executive committee. Jonathan Dancer (pictured) the managing …
Takeda offers $2.2 billion to resolve Actos damages claims
April 1, 2015Sales and Marketing Actos, Cancer, Takeda, bladder, diabetes, heart, pioglitazone
Takeda has attempted to settle its hefty damages bill over claims it was hiding cancer risks in its diabetes drug …
Merck lines up early-stage Keytruda combo trial
April 1, 2015Research and Development, Sales and Marketing Cancer, Merck, entinostat, keytruda, pd1, pembrolizumab, syndax
Merck is planning for Keytruda’s future by launching early-stage trials of the drug in combination with an investigational treatment from …
Pfizer appoints inflammation and immunology head
April 1, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Charles Reay Mackay, Pfizer
Professor Charles Reay Mackay is joining US pharma giant Pfizer as the chief scientific officer of its inflammation and immunology …
Teva bolsters neurology unit through Auspex deal
March 31, 2015Sales and Marketing CNS, SD-809, Teva, Tourette syndrome, auspex, deutetrabenazine, neurology
Teva is significantly enhancing its neurology business by acquiring US biopharma firm Auspex in a deal worth $3.5 billion. Teva …
Novartis drug to treat iron overload gets US nod
March 31, 2015Sales and Marketing FDA, Novartis, blood, deferasirox, exjade, iron, jadenu
Novartis’ iron overload drug Jadenu has been given the green light by US regulators to treat patients with a serious …
Pfizer is pharma’s biggest advertiser
March 31, 2015Medical Communications, Sales and Marketing AbbVie, AstraZeneca, Pfizer, advertising, adverts, dtc, lilly
US giant Pfizer spends far more on direct-to-consumer advertising than any other pharma firm according to new data from Kantar …
Merck Serono in $826m immuno-oncology deal
March 31, 2015Research and Development, Sales and Marketing Intrexon, Merck, Merck Serono, T cell, biopharma, cart, immuno-oncology, t-cell
Merck Serono has announced a significant deal with Intrexon to develop and bring new cancer treatments to market. The German …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
